Latest Conference Articles

Younger Age and Higher HbA1c Among Factors Linked to CGM Uptake in New Study

Younger Age and Higher HbA1c Among Factors Linked to CGM Uptake in New Study

June 6th 2022

ADA

ADA 2022: Younger age, insulin use, higher HbA1c, and higher diabetes distress were found to be associated with CGM uptake in prospective study.

Patients with Diabetes Up to 4-times More Likely to Develop Long COVID-19

Patients with Diabetes Up to 4-times More Likely to Develop Long COVID-19

June 4th 2022

ADA

ADA 2022: In a new literature review, 43% of studies included identified diabetes as a potent risk for developing post-acute sequelae of COVID-19.

Tirzepatide Treatment Leads to Weight Loss of up to 22.5% in SURMOUNT-1 Clinical Trial

Tirzepatide Treatment Leads to Weight Loss of up to 22.5% in SURMOUNT-1 Clinical Trial

June 4th 2022

ADA

ADA 2022: Tirzepatide led overall to weight loss of up to 22.5% of baseline body weight with persons taking the 15 mg dose losing an average of 52 pounds.

Tirzepatide Slows Renal Decline in T2D Patients with CKD in First Analysis of Dual Agent on Kidney Function

Tirzepatide Slows Renal Decline in T2D Patients with CKD in First Analysis of Dual Agent on Kidney Function

June 3rd 2022

ADA

ADA 2022: Tirzepatide, a GIP/GLP-1 receptor agonist, reduced a composite of kidney events in patients with type 2 diabetes and at increased cardiovascular risk in an analysis of SURPASS-4.

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

NAVIGATOR: Tezepelumab Reduces Asthma Exacerbations by More than Half

May 20th 2022

ATS

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

Review of Biologic Treatments for Asthma Finds Inconsistent Effects on Airway Hyperresponsiveness

Review of Biologic Treatments for Asthma Finds Inconsistent Effects on Airway Hyperresponsiveness

May 19th 2022

ATS

ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.

Tezepelumab Reduces Asthma Exacerbations by More than Half, Reports NAVIGATOR Study Author

Tezepelumab Reduces Asthma Exacerbations by More than Half, Reports NAVIGATOR Study Author

May 19th 2022

ATS

Njira Lugogo, MD, sat down with Patient Care Online to discuss findings from the prespecified exploratory analysis of the NAVIGATOR study that she presented at ATS 2022.

Real-world Data Showed Mepolizumab Reduced Exacerbations, Oral Corticosteroid Use in Adults with Severe Asthma

Real-world Data Showed Mepolizumab Reduced Exacerbations, Oral Corticosteroid Use in Adults with Severe Asthma

May 18th 2022

ATS

ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.

Novel PDE4B Inhibitor Slows Lung Function Decline in IPF: Phase 2 Data from Boehringer Ingelheim

Novel PDE4B Inhibitor Slows Lung Function Decline in IPF: Phase 2 Data from Boehringer Ingelheim

May 17th 2022

ATS

ATS 2022: The investigational PDE4B inhibitor slowed pulmonary decline in patients with IPF, both alone and with background use of approved antifibrotics.

NAVIGATOR Data Presented at ATS 2022 Show Improved Clinical Responses to Treatment with Tezepelumab vs Placebo

NAVIGATOR Data Presented at ATS 2022 Show Improved Clinical Responses to Treatment with Tezepelumab vs Placebo

May 16th 2022

ATS

ATS 2022. A greater proportion of tezepelumab-treated patients with severe, uncontrolled asthma achieved on-treatment clinical responses than placebo-treated patients.